TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Arrhythmias of Interest Incidence Rate, 48 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Arrhythmias of Interest Incidence Rate, 14 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of women reaching active phase within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Sputum Samples Positive for Bacterial Pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Sputum Samples Positive for Viral Pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Implant and prosthetic success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment effectiveness for aphthous stomatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Alive and Free of Respiratory Failure at Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Overall Mean Survival
Endpoint domain: Mortality/survival
Primary endpoint: Western Ontario and McMaster Universities (WOMAC) OA Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Respiratory System Elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under Curve (AUC) of lamivudine after qd and bid dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin of lamivudine after qd and bid dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of lamivudine after qd and bid dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Restoration of blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in ApoCIII levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Reduction of triglycerides and very low density lipoprotein (VLDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in Peripheral Artery Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sutures complications
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Leuprolide Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: State-Trait Anxiety (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Morning Blood Pressure/Evening Blood Pressure Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body fat levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the blood glucose time curve (AUCbg) from 0 to 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of resistant gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health Gain as measured by the change in Physical Component Summary (PCS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of positive mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: occurrence of preterm adverse obstetrical event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with EGFR positive mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in PAFI O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum plasma concentration (Cmax) of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve (AUC) of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration (Cmax) of SP2086
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve (AUC) of SP2086
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of volunteers with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of the ATOMIC program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utility of the ATOMIC program
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of motor units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Size of motor units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 28 Day Parasitological Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic paravertebral block (TPVB) performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functional Outcome of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Difference in endtidal PCO2 and PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brain Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone Turnover Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Overgrowth of Oral Microbiota in Their Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Major Depression Inventory (MDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder 7-item (GAD-7) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Structured Interview Guide for the Hamilton Depression Scale and Inventory of Depressive Symptomatology-Clinician Rated (SIGHD-IDSC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of compression garments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Range of motion (ROM) of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Drug spread level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-week progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of moderate to severe distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of the device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PPARg mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine abundance in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PFS - Time to Event
Endpoint domain: Mortality/survival
Primary endpoint: PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H3N2 Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With 4 Fold Rise in Serum Antibody Concentration of B-type Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of persistence on Active Surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body Composition - Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieve >5mmHg Reduction in Systolic Blood Pressure From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Non-HDL (High Density Lipoprotein Cholesterol) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Adverse Events Recorded
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Days Per Week TTNS Was Used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Satisfaction of Daily Use of TTNS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional outcomes measured by IKDC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcomes measured by Tegner-Lysholm scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of methylation in histone H2A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of methylation in histone H2B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of methylation in histone H3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of endometrial malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PK data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AEs
Endpoint domain: Adverse events/effects
Primary endpoint: changes in laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Villalta PTS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross sectional area of gastric antrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in specific phobia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Saturation Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart Rate (pulse) Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standardized Tobacco Susceptibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Capillary permeability (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in number of anti-VEGF required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of objective tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical Success in the Intent to Treat (ITT) population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success in the Clinically Evaluable (CE) population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with INR >= 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response at Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Resolution or improvement of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge about asthma
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Willingness to pursue preemptive living donor transplant
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean minimal coronary-artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Correctly Identified Actual Negatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCCB overall composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distance traveled by the pancreatic tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Disease Activity Score (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CoQ10 concentration in tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline soluble P-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline von Willebrand factor (VWF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline augmentation index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline fractional exhaled nitric oxide (FeNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Classification accuracy of brain patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Persistent CTC and biochemical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Positive Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aspiration Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Daily Crying Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of complete wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased objective amplitude of accommodation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of HDAC inhibitor AR-42
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of IPI 493
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving seroconversion and seroprotection for HI antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfaction with eyelashes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patients' overall satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Colony Forming Units (CFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Variation of liver fibrosis percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of MGd
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oral Microbiota colony counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood fructosamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-year Relapse Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Responders as Assessed by DAS28 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants born to HIV-infected mothers who have acquired HIV
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of HIV-exposed infants tested for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of pregnant women making at least four antenatal clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity and specificity of microRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival in patients with acute and chronic heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Left Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Immune Response by Levels of Unfractionated Gag, Pol, and Nef-specific IFN-gamma Following a 3-dose Vaccine Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune Response by Levels of Unfractionated Gag, Pol, and Nef-specific IFN-gamma Following a 2-dose Vaccine Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Arterial Thromboembolic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: British Ability Scale (BAS) II Word Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: British Ability Scale (BAS) Digit Span Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CogTrack Precision Cognitive Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: maximum tolerated dose (MTD) of Cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of subjects experiencing toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Daily opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity of Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Energetic/Fatigue VAS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Interventricular septum position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Short Form (SF) question 3 (BPI-SF3)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: non-transient facial erythema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Synovial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient Genomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time to 95% healing of treated burn wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Individual maximum power output (Pmax) in watt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients initiating TNFα blockers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sleeping or Resting Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose and insulin metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Autonomic cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in retention-in-care behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in HIV RNA viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Modified Schober's test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of toxicities and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary caregiver's mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's cognitive, social, and emotional development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Days Alive and Out of the Hospital Within 30 Days of Surgery
Endpoint domain: Mortality/survival
Primary endpoint: percentage of responders to diuretic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who develop adverse effects to diuretics
Endpoint domain: Adverse events/effects
Primary endpoint: Foveal avascular zone (FAZ) area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central foveal retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of Volunteers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion avoiding splenectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Biological markers of Parkinson's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electronic Apex locator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler-derived renal venous flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CSA-AKI incidence
Endpoint domain: Adverse events/effects